C-terminal specific "Active GLP-1" Matched Antibody Pair
Description
Mouse monoclonal antibodies
Specificity
This uses HYB 147-06 as capture antibody in combination with biotinylated detection antibody ABS 033-10B exclusively to measure GLP-1(7-36)amide in biological samples. GLP-1(7-36)amide is the principal active form of the peptide, and has been estimated to make up about 70% of the physiological response. Relative to measuring both active forms of GLP-1 together, the responses are reduced by not measuring the approximately 30% contribution of GLP-1(7-37) to the overall response. There is no cross-reactivity with any extended or truncated physiological form of GLP-1(7-36)amide.
HYB 147-06-02
495 €
ABS 033-10B-005
380 €
Total
875 €
Matched Pair Price
785 €
Immunogen
Synthetic GLP-1 (7-17)
Application
ELISA
Content
200 µL capture antibody and 50 µl detection antibody. 1 mg/mL +/- 15%. See Certificate of Analysis for details.
Target
Glucagon-like peptide 1(7-36)amide (GLP-1(7-36)amide) is the principal active form of GLP-1, the other being GLP-1(7-37). GLP-1 is a peptide hormone of the glucagon family, produced by the L cells of the intestinal mucosa from the same prohormone as glucagon. The active forms are potent stimulators of glucose-dependent insulin secretion. The sequence of GLP-1 is fully conserved in all mammalian species examined so far.
Application 1
ELISA HYB 147-06 (as capture antibody) forms a sandwich ELISA pair with ABS 033-10B (as biotinylated detection antibody) for measuring the principal active form of GLP-1.
This uses HYB 147-06 as capture antibody in combination with biotinylated detection antibody ABS 033-10 exclusively to measure GLP-1(7-36)amide in biological samples. GLP-1(7-36)amide is the principal active form of the peptide, and has been estimated to make up about 70% of the physiological response. Relative to measuring both active forms of GLP-1 together, the responses are reduced by not measuring the approximately 30% contribution of GLP-1(7-37) to the overall response. There is no cross-reactivity with any extended or truncated physiological form of GLP-1(7-36)amide. Specimens must be collected into tubes containing an adequate amount of DPP-4 inhibitor (in addition to routine peptidase inhibitors) to prevent therapid in vitro degradation of the active peptide.